I’m excited to discuss some of our stock-picking techniques! At our fund, we dive deeply into biotech businesses that are in the clinical stage, concentrating on their “Crown Jewel” — the lead medicine that is currently under development. This is the method we use:
Comprehending the Science: We assess the medication’s mode of action and its capacity to treat particular ailments. Our intuition has been refined over the course of more than 20 years of experience to forecast clinical trial success and FDA approval.
Evaluating Market Potential: We project if the medication has what it takes to become a blockbuster that brings in more than $1 billion in revenue annually. This important phase aids in determining the product’s potential market impact.
Valuation Beyond Tradition: We employ a different approach to valuation than relying on conventional financial formulas. We take into account the medication’s prospects of passing clinical studies, receiving FDA approval, and being successful on the market. This strategy recognizes the distinct growth trajectory of early-stage bio equities and is customized for them.
Join the conversation with Evergrowth BioHealthcare Capital and let’s work together to uncover the potential of biotechnology investments!